Evidence map›Paper›PMID 39163171›Full record

ArticleMolecular pharmaceutics2024

Fabrication of Hybrid Coated Microneedles with Donepezil Utilizing Digital Light Processing and Semisolid Extrusion Printing for the Management of Alzheimer's Disease.

Paraskevi-Kyriaki Monou, Eleftherios G Andriotis, Eirini Saropoulou, Emmanouil Tzimtzimis, Dimitrios Tzetzis, Georgios Komis, Chrysanthi Bekiari, Nikolaos Bouropoulos, Efterpi Demiri, Ioannis S Vizirianakis and 1 more

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Topical Donepezil for Cholinergic Modulation in Chronic Wound Repair.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Paraskevi-Kyriaki MonouDepartment of Pharmacy, Division of Pharmaceutical Technology, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
Eleftherios G AndriotisDepartment of Pharmacy, Division of Pharmaceutical Technology, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
Eirini SaropoulouDepartment of Pharmacy, Division of Pharmaceutical Technology, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
Emmanouil TzimtzimisDigital Manufacturing and Materials Characterization Laboratory, School of Science and Technology, International Hellenic University, 14km Thessaloniki - N. Moudania, Thermi GR, Thessaloniki 57001, Greece.
Dimitrios TzetzisCenter for Interdisciplinary Research and Innovation (CIRI-AUTH), Thessaloniki 57001, Greece.
Georgios KomisDepartment of Botany, School of Biology, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
Chrysanthi BekiariFaculty of Veterinary Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
Nikolaos BouropoulosDepartment of Materials Science, University of Patras, Rio, Patras 26504, Greece.
Efterpi DemiriDepartment of Plastic Surgery, Medical School, Papageorgiou Hospital, Aristotle University of Thessaloniki, Ag. Pavlos, Thessaloniki 56429, Greece.
Ioannis S VizirianakisCenter for Interdisciplinary Research and Innovation (CIRI-AUTH), Thessaloniki 57001, Greece.ORCID 0000-0003-1459-9774
Dimitrios G FatourosDepartment of Pharmacy, Division of Pharmaceutical Technology, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.ORCID 0000-0003-2361-4198

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microneedle (MN) patches are gaining increasing attention as a cost-effective technology for delivering drugs directly into the skin. In the present study, two different 3D printing processes were utilized to produce coated MNs, namely, digital light processing (DLP) and semisolid extrusion (SSE). Donepezil (DN), a cholinesterase inhibitor administered for the treatment of Alzheimer's disease, was incorporated into the coating material. Physiochemical characterization of the coated MNs confirmed the successful incorporation of donepezil as well as the stability and suitability of the materials for transdermal delivery. Optical microscopy and SEM studies validated the uniform weight distribution and precise dimensions of the MN arrays, while mechanical testing ensured the MNs' robustness, ensuring efficient skin penetration. In vitro studies were conducted to evaluate the produced transdermal patches, indicating their potential use in clinical treatment. Permeation studies revealed a significant increase in DN permeation compared to plain coating material, affirming the effectiveness of the MNs in enhancing transdermal drug delivery. Confocal laser scanning microscopy (CLSM) elucidated the distribution of the API, within skin layers, demonstrating sustained drug release and transcellular transport pathways. Finally, cell studies were also conducted on NIH3T3 fibroblasts to evaluate the biocompatibility and safety of the printed objects for transdermal applications.

Indexed as

Administration, CutaneousAlzheimer DiseaseCholinesterase InhibitorsDonepezilDrug Delivery SystemsNeedlesPrinting, Three-DimensionalAnimalsDrug LiberationHumansMiceNIH 3T3 CellsSkinSkin AbsorptionTransdermal PatchCholinesterase InhibitorsDonepezil3D printingAlzheimer’s diseasemicroneedlesskin deliverytransdermal delivery

Identifiers

PMID39163171
PMCPMC11372831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.